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or the past decade cell transplantation for end-stage heart failure has drawn a lot of attention from both basic and clinical researchers. Many studies, including ours, [1] [2] [3] have demonstrated favorable results in animal experiments, and several clinical trials are now underway with promising outcomes. [4] [5] [6] [7] Although skeletal myoblasts (SMs) are favored as donor cells for transplantation, there is no clear evidence that SMs transdifferentiate into cardiomyocytes, and ventricular arrhythmia may be a major drawback with this cell source in human applications. 8 Bone marrow is another cell source that has been used clinically, [5] [6] [7] the advantages of which are that abundant autologous cells can be harvested and, in contrast to SMs, bone marrow cells (BMCs) have the potential to transdifferentiation into cardiomyocytes. [9] [10] [11] Moreover, they have the unique capacity of migration to the injured site of the heart, 12, 13 which may enable noninvasive strategies of BMC transplantation after intravenous (IV) injection. However, it remains unclear whether systemic administration of BMCs is as effective as direct transplantation into the failing heart. There has not been a direct comparison of intramyocardial (IM) injection and IV infusion. In addition, although there are a number of reports of BMC transplantation to ischemic hearts, only a little is known about the process in nonischemic dilated cardiomyopathy (DCM). [14] [15] [16] [17] Therefore, the purpose of this study was to compare the efficacy of BMC transplantation among various routes of cell delivery, and thereby elucidate how BMCs should be transplanted, using mouse models of acute and old myocardial infarction (AMI and OMI) and DCM.
Methods

Animals
Male syngeneic C57Bl/6 mice were used as donors and recipients in this study to simulate autologous transplantation in the clinical setting. All experimental procedures were performed by experienced surgeons (H.N. and Y.S.) in accordance with the guidelines for Animal Experiments of Kyoto University, which conforms to the law of "Guide for the Care and Use of Laboratory Animals" in Japan.
with phosphate-buffered saline solution (PBS) supplemented with 2% fetal bovine serum. To isolate the mononuclear cells, a gradient centrifugation method with Percoll was used. The cells were suspended in PBS to obtain concentrations of 1×10 7 cells in 0.01 ml when they are injected into the myocardium, or 1×10 7 cells in 0.1 ml when injected intravenously.
AMI and OMI Models
Wild male mice (10 weeks old, weighing an average of 25 g) were intubated after being anesthetized with ethyl ether gas, and were ventilated at 100 breaths/min. Anesthesia was maintained during the operation with 1-2% isoflurane. The heart was exposed through a left thoracotomy, the left anterior descending artery (LAD) was identified and then ligated 0.5 mm distally from the edge of the left auricle with an 8-0 polypropylene suture. Regional myocardial ischemia was confirmed by the rapid occurrence of akinesis and color change. The muscle layer and skin incision were closed with 4-0 polypropylene sutures. All mice underwent the first echocardiographic assessment 6 h after ligation in the AMI model, and 4 weeks after ligation in the OMI model. If the akinetic area was less than 25% or more than 50% from the first echocardiographic evaluation, the mice were excluded from this study.
Doxorubicin-Induced Cardiomyopathy Model
Wild male mice (8 weeks, weighing an average of 23 g) received peritoneal injections of doxorubicin (2.75 mg/kg, 6 times per 2 weeks) to induce nonischemic DCM. If the left ventricular end-diastolic dimension (LVDd) of the first echocardiography was less than 3.00 mm, the mice were excluded from the study. Fig 1 shows the experimental design: 3 models were set according to the etiology (ie, AMI, OMI and DCM, n=36, respectively). The mice that met the criteria were entered into the study just after the first echocardiographic assessment. In the AMI model, BMCs were transplanted just after the first echocardiographic assessment, which was performed 6 h after coronary ligation. The timing of 6 h was set to simulate primary care for AMI in the clinical setting. In the OMI model, transplantation was performed 4 weeks later to simulate the chronic phase of infarction. In the DCM model, BMCs were administered 4 weeks after the final injection of doxorubicin. Animals in each model were divided into 3 groups according to delivery routes: IM (IM-group, n=12), IV (IV-group, n=12), and control (C-group, n=12). To maintain uniform experimental conditions, the mice in each delivery route group underwent the same procedures such as thoracotomy, IM and IV injection. Each group received BMC injections as follows: IM-group received IM BMCs and IV PBS; IV-group received IV BMCs and IM PBS; C-group had IM and IV PBS. Details of injections are described below. Left ventricular (LV) dimensions and function were followed-up by echocardiography, and a histological study was performed after death.
Experimental Design and Groups
Cell Transplantation IV injection of BMCs (2×10 7 ) suspended in 200 l of PBS was performed through the tail vein of the recipient mouse using a 27-gauge needle/syringe. Direct injection into the myocardium was done using a 31-gauge needle with Hamilton syringe containing a 20-l suspension of BMCs (2×10 7 ) through a U-stay stitch with a 7-0 polypropylene suture on the epicardium, which was closed just after injection to avoid leakage. Injection sites were selected according to the model: (1) mice in the AMI or OMI model received a single injection into the peri-infarct region, (2) mice in the DCM model received 2 injections (10 l each) into the LV anterior wall and lateral wall through a single U-stay stitch. PBS injections were performed for controls in the same fashion. Direct injection was conducted through a left thoracotomy under general anesthesia and mechanical ventilation as described previously.
Functional Assessment by Echocardiography
Every mouse underwent 2 echocardiographic assessments of LV function at intervals of 4 weeks (Fig 1) . The first assessment was made 6 h after ligation of the LAD in the AMI model, 4 weeks after ligation in the OMI model, or 4 weeks after the final injection of doxorubicin in the DCM model. The second assessment was done 4 weeks after the first. The assessments were conducted with 15-6 MHz UltraBand High-Frequency Linear Transducer (Model 21390A with HP SONOS 5500 imaging system, Agilent Technologies, Andover, MA). Mice were anesthetized with 0.5% isoflurane during the assessment. Images were recorded from the left parasternal windows in the right lateral decubitus position. The following variables were derived from M-mode tracing at the papillary muscle level: LVDd (mm), LV end-systolic dimension (LVDs, mm), LV wall thickness (LVWTh, mm), and fractional shortening (FS, %). Fractional area change (FAC, %) and the percentage of akinetic endocardial length to the whole LV endocardial circumference (AL, %) were also calculated from the midventricular short axis view at end-diastole. LVWTh/LVDd was calculated in the DCM model. All measurements were performed in a blind fashion according to the American Society for Echocardiology, and averaged over 3 consecutive cardiac cycles.
Histology
After the second echocardiographic assessment, all mice were killed. Their hearts were exposed and injected with PBS through the apex, then perfusion-fixed with 4% paraformaldehyde in PBS for 20 min, before removal and protection with 30% sucrose in PBS overnight. The specimens were cryoembedded and sectioned in 5-m thickness for examination of GFP by fluorescence microscopy to identify donor cells, and also for processing with hematoxylineosin staining. In the AMI and OMI models, the MI scar area was calculated from the measured diameter before sectioning. Immunohistochemical staining was performed for GFP (anti-GFP/MBL), DAPI (dapi nucleic acid stain/ molecular probes), troponin I (troponin I-C/Santa Cruz Biotechnology), and -sarcomeric actin (clone -Sr-1, Dako Cytomation, Glostrup, Denmark). The sections were incubated overnight at 4°C with primary antibodies, as described above, in the presence of 0.1% saponin after blocking. Fluorescein isothiocyanate (FITC)-labeled antibodies to goat immunoglobulin G and Texas red-labeled antibodies to rabbit immunoglobulin G were used as secondary antibodies. Cell nuclei were stained with DAPI. After enclosing with FluorSave Reagent, the slides were observed with an Olympus BX41 microscope with CCD (MagnaFire TM, Olympus, Tokyo, Japan) camera using FITC and Texas Red filters and images were recorded using a digital camera with MagnaFireTM2.1 software.
Data Analysis
All data are expressed as the mean values ± standard error of the mean (SEM). Comparisons of echocardiographic data concerning delivery route were performed by repeated measures analysis of variance (ANOVA). Comparisons of scar area concerning delivery route were performed by 1-way ANOVA. If significance was recognized for the route effect, post hoc comparisons were made among the groups in each model, using Fisher's protected least significant difference method. All statistical analyses were performed with computer software (Stat View for Windows version 5.0, SAS Institute Inc, Cary, NC, USA). A probability value <0.05 was considered statistically significant.
Results
Mortality
There were 6 deaths in the AMI model, and 10 in the OMI model, mostly in the perioperative period and mainly caused by strong adhesions after the second thoracotomy. In the DCM model 11 mice died in the perioperative period. There were no deaths after BMC injection. There were no significant differences in mortality between the 3 delivery route groups.
Echocardiography
All results of the echocardiographic measurements are shown in Tables 1,2 and 3 . There were no differences in the first assessment data for the 3 delivery groups in each model. Table 1 summarizes the first and second assessment data in the AMI model. In the analysis of LVDd, LVDs, AL, and FAC, there was a strong route effect. LVDd and LVDs in the IM-and IV-groups were significantly smaller than in the C-group, and FAC in those 2 groups was larger than that in the C-group. AL in the IMgroup was smaller than that in the C-group. There were no significant differences between the IM-and IV-groups for any variable.
AMI Model
OMI Model Table 2 summarizes the data for the OMI model. LVDd and LVDs in the IM-group were smaller than the values obtained for the IV-and C-groups. FS in the IMgroup was larger than in the IV-or C-group. AL in the IMgroup was smaller than in the IV-or C-group. Table 3 shows the data for the DCM model. LVDd in the IV-group was smaller than in the IMor C-group. LVDs in the IV-group and IM-group was smaller than in the C-group. LVWTh/LVDd in the IVgroup was larger than in the C-groups. FS in the IM-and IV-groups was larger than in the C-group. Table 4 shows the MI scar area calculated from the measured diameter of the perfusion-fixed specimen. The scar area in the IM-group was smaller than that of the C-group in the AMI model. Although there were no significant differences among the 3 delivery route groups in the OMI model, the scar area of the IM-group tended to be smaller than that of the C-group.
DCM Model
Myocardial Infarction (MI) Scar Area
Histology
Fluorescence microscopic examination for GFP revealed engraftment of transplanted BMCs as follows. In the AMI model, donor cells were equally detected in the scar and peri-infarct areas in both the IM-and IV-groups (Figs 2A,B) . In the OMI model, transplanted cells were engrafted in or near the peri-infarct region in the IM-group (Fig 2D) , but less donor cells were seen in the IV-group (Fig 2E) . In the DCM model, GFP cells were confined to the injection site in the IM-group (Fig 2G) , whereas in the IV-group GFPpositive cells were diffusely scattered throughout the LV wall (Fig 2H) . GFP-positive tissue was not found in the Cgroup of the AMI, OMI, and DCM models ( Figs 2C,F,I ). In the AMI model, GFP-positive tissue in the scar area stained for -sarcomeric actin ( Figs 3A,B) . The location of GFPpositive cells in the scar and peri-infarct areas was demonstrated by comparing the fluorescent image with specimens stained with Hematoxylin and eosin or Masson trichrome ( Fig 4) . In the OMI model, the engrafted cells were also confirmed by anti-GFP immunohistological staining (Fig 5A) . Those specimens were also stained for DAPI and troponin I (Figs 5B-D) . In the DCM model, GFP-positive cells were also positive for anti-GFP staining and troponin I (Figs 6A-D). Under higher magnification GFP-positive cells had a striated structure that was integrated into the myocardium, apparently mature cardiomyocytes (Fig 6E) .
Discussion
The major findings of the present study are as follows. (1) In the AMI model, both the IV and IM delivery routes reduced cardiac remodeling; however, only the IM delivery was effective in the OMI model. (2) In the DCM model, both IV and IM delivery improved systolic function; however, cardiac remodeling was reduced only by IV delivery. Therefore, IV delivery is considered to be better than IM delivery. The first finding was anticipated, because migration of BMCs is in part driven by chemokines that are released at the injury site. 18, 19 It would be reasonable to consider that BMCs migrate only to the area of AMI, but not to the infarct scar, because BMCs are mobilized to the actively injured region. On the other hand, the second finding was not been expected. When considering the pathology of DCM, IV injection would deliver BMCs throughout the whole heart by migration, whereas the IM approach limits BMCs to the injection site, as shown in the histological study. We suspected that BMCs in a limited area by IM delivery would improve systolic function, but there were not enough implanted BMCs to reduce cardiac remodeling, because fibrosis of the extracellular matrix was not reduced in the area of LV wall not injected with IM cells.
Compared with other types of donor cells, BMCs have an intriguing characteristic: the capacity of migration to injured sites. 12, 13, 20 Orlic et al showed that BMCs, mobilized by G-CSF and stem cell factor, migrate to the infarcted region, regenerated the de novo myocardium, and improved contractile function and survival in a mouse model of AMI. 20 Kocher et al intravenously injected cytokine-mobilized CD34-positive BMCs, which were purified by flow cytometry using a fluorescence activated cell sorter, in a nude rat model of AMI. 12 They documented that bone marrowderived angioblasts prevented cardiomyocyte apoptosis, reduced remodeling, and improved cardiac function. Toma et al demonstrated that mesenchymal stem cells (MSCs) administered into the LV cavity migrated through the systemic circulation and resettled in the myocardium. 21 We consider that this migratory capacity of BMCs is very important for their clinical use, because it enables local delivery of the cells by systemic administration.
Barbish et al investigated cell kinetics, body distribution, and colonization in the infarcted myocardium after systemic delivery of 99m Tc-labeled bone marrow-derived MSCs. 22 They concluded that entrapment of the donor cells in the lungs limited the number of colonized cells in the heart. Although our findings are basically compatible with their results, their donor cells differed from ours in that they transplanted culture-expanded MSCs, whereas we used freshly isolated mononuclear BMCs. Barbish et al described expanded MSCs as relatively large, activated, and expressing adhesion molecules, which makes them easily trapped in the lungs. In fact, in our preliminary study, we experienced high mortality because of respiratory distress when 1×10 6 cultured MSCs were injected IV into the mice, whereas there was no mortality in the present study when 2×10 7 fresh BMCs were administered, so we consider there was less entrapment in the lungs.
Agbulut et al transplanted 6×10 6 BMCs into the myocardium of doxorubicin-induced DCM mice and confirmed their differentiation into cardiomyocytes and endothelial cells. They concluded that the functional benefits were questionable because only a very small number of cells had transdifferentiated. 17 In the present study, however, we demonstrated improved LV function and engrafted GFP-positive tissue in the LV wall. Among the GFP-positive cells, we also found donor cell-derived -sarcomeric actin-positive tissue. On the other hand, Scorsin et al showed in their report of fetal cardiomyocyte transplantation in a doxorubicin-induced DCM model that functional improvement was possible even without the sustained presence of transplanted cells. 14 Recently, Xu et al demonstrated that bonemarrow-derived stem cells reduce the expression of extracellular matrix genes and thereby inhibit LV remodeling and improve heart function. 23 Therefore, we consider that transplanted BMCs contributed to the improvement in LV function by 2 mechanisms: (1) transdifferentiation into cardiac or vascular phenotypes and (2) releasing growth factors that induce angiogenesis, reduce apoptosis of recipient cells, and also reduce alterations in the extracellular matrix. By those mechanisms the infarction size was reduced, as demonstrated in the direct measurement of MI scar area.
We transplanted 2×10 7 BMCs, which is the largest number used in the relevant studies, considering the body size of mice, and may have influenced the histological results in which relatively more engrafted donor cells were observed. Approximately 1×10 6 to 1×10 7 cells were transplanted into rats in most of the other studies. The volume of cell suspension (20 l) eventually limited the number of cells for IM injection to the tiny hearts of mice, whereas it may be possible to increase the number of cells for IV delivery. Therefore, the number of cells (2×10 7 ) was the maximum number for IM injection and so to directly compare the 2 delivery routes, we used the same number of cells. Further investigation is required to assess the optimal number of cells for IV administration. 
Study Limitations
First, although doxorubicin-induced DCM is an established model, it is uncertain whether all the results of this study can be applied to human DCM, the etiology of which is not drug-induced but idiopathic. Second, cardiac function was assessed only by echocardiography. Although cardiac catheterization might have given better information for assessment of global cardiac function, we dismissed that method because of our concerns about the technical accuracy in the mice's tiny hearts. We believe that our data obtained from clear images obtained with a 15-MHz linear transducer were reliable enough. Third, quantitative analysis of angiogenesis and myogenesis was not done. Although several earlier studies have some information about those issues, 24, 25 further investigation is necessary to understand the mechanism of functional improvement. Finally, intracoronary delivery of BMCs was not investigated in this study. Intracoronary infusion via catheter 26 is one of the most feasible modes of BMC delivery in the clinical setting, but BMC injection into the coronary artery of a mouse was not possible. Recently, Yokoyama et al showed that retrograde delivery of BMCs via the coronary vein induced angiogenesis and improved the function of the infarcted heart. 27 Retrograde infusion might be an alternative strategy in the clinical setting. Further evaluation and direct comparison of delivery routes is required in a large-animal model.
In conclusion, both IV and IM delivery of BMCs reduced cardiac remodeling in an AMI model; whereas, in the OMI model, IM delivery was more effective, and IV administration was superior in DCM. The delivery route should be selected according to the etiology of heart disease to optimize the efficacy of BMC transplantation.
